Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology Arcutis today announced that the JCAD published an evaluation of formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%.